ReviewRheumatology (Oxford, England)2020
The patient's perspective: are quality of life and disease burden a possible treatment target in systemic lupus erythematosus?
Review in Rheumatology (Oxford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial.Lupus science & medicine · 2025Trial
- Longitudinal Trajectories and Predictors of Health-Related Quality of Life in Systemic Lupus Erythematosus: A 2-Year Longitudinal Cohort Study.Rheumatology and therapy · 2026Article
- Evaluating disease burden in German AAV patients using the AAV-PRO: associations with disease activity, physical function, depression, fatigue and quality of life.Journal of patient-reported outcomes · 2026Article
- Association of physicians' Big Five personality traits with shared decision-making in patients with SLE.Rheumatology (Oxford, England) · 2025Article
- Observational
- Patient perspectives on rheumatic and musculoskeletal diseases: insights from a large-scale survey.Clinical rheumatology · 2025Article
- Impact of quality of life on overall work productivity impairment and activity impairment of patients with systemic lupus erythematosus: the PEONY study.Lupus science & medicine · 2025Article
- Impact of disease activity patterns on health-related quality of life (HRQoL) in patients with systemic lupus erythematosus (SLE).Lupus science & medicine · 2024Article
- The NYMERIA Study: A Real-World, Multicentre Contemporary Assessment of Disease- and Patient-Related Burden and Treatment Strategies in Patients with Systemic Lupus Erythematosus.Mediterranean journal of rheumatology · 2024Article
- Vision-Related Quality of Life in Patients with Systemic Lupus Erythematosus.Healthcare (Basel, Switzerland) · 2024Article
- Exploring the Perspectives of Patients Living With Lupus: Retrospective Social Listening Study.JMIR formative research · 2024Article
- A tool to assist rheumatologists to engage their lupus patients: the Purple Butterfly.Rheumatology advances in practice · 2024Article
- The relationship of neutrophil-to-lymphocyte ratio with health-related quality of life, depression, and disease activity in SLE: a cross-sectional study.Rheumatology international · 2023Article
- Treat-to-Target in Systemic Lupus Erythematosus: Reality or Pipe Dream.Journal of clinical medicine · 2023Review
- Body Image, Depression Symptoms, and Health-Related Quality of Life in Black Women With Systemic Lupus Erythematosus.Nursing for women's health · 2022Article
- Medication decision-making and adherence in lupus: patient-physician discordance and the impact of previous 'adverse medical experiences'.Rheumatology (Oxford, England) · 2022Article
- The impact of distress disclosure and anxiety on the association between social support and quality of life among Chinese women with systemic lupus erythematosus.Frontiers in psychiatry · 2022Article
- Total Glucosides ofFrontiers in pharmacology · 2022Review
- Effects of Exercise Intervention on Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis of Controlled Trials.Healthcare (Basel, Switzerland) · 2021Review
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A few decades ago, the therapy goal of patients with systemic lupus erythematosus (SLE) was survival and the prevention of organ failure. Today, clinical remission and low disease activity are believed to be the optimal therapeutic targets. These aims are difficult to reach for many patients, but they still do not address the health-related quality of life (QoL) that is significantly impaired in SLE patients. Even in the state of remission, QoL and fatigue are insufficient controlled. Thus, patient-oriented research is essential to design new strategies for the management of lupus patients. The INTEGRATE project analyses the patients' and physicians' perspectives to pave the way to design an innovative therapeutic strategy for lupus and focuses on the multifaceted dimensions of the disease burden. Shared decision making (SDM) could include the patient's perspective of SLE to treatment strategy and consider QoL and the burden of lupus into the process of therapy decision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.